The Disease Burden and Societal Costs of Hereditary Angioedema

• DOI: 10.1016/j.jaip.2023.03.032
• Publication Date: 2023-03-27T16:07:19Z
• Authors: Lauré M. Fijen; Philip C.G. Klein; Danny M. Cohn; Tim A. Kanters
• Keywords: Hereditary Angioedema

According to the current treatment guidelines, goals of patients with hereditary angioedema (HAE) are achieve total control disease and normalize patients' lives.This study aims establish entire burden HAE comprising control, satisfaction, reductions in quality life, societal costs.Adult under at Dutch national center reference completed a cross-sectional survey 2021. The consisted different questionnaires: angioedema-specific questionnaires (4-week Angioedema Activity Score Control Test), life (Angioedema Quality Life [AE-QoL] questionnaire EQ-5D-5L), Treatment Satisfaction Questionnaire for Medication (TSQM), costs (iMTA Medical Consumption iMTA Productivity Cost Questionnaire).The response rate was 78% (69 88). sample had mean 16.61, 36% participants poorly controlled as expressed by Test. 30.99 AE-QoL 0.873 EQ-5D-5L utility value. Utilities dropped 0.320 points during an attack. TSQM scores ranged from 66.67 75.00 across its 4 domains. On average, per year incurred €22,764, predominantly existing HAE-medication costs. Total showed substantial variation between patients.This describes among These results can inform cost-effectiveness analyses that aid reimbursement decisions treatments.